Leonard E. Post - 05 Jun 2025 Form 4 Insider Report for CG Oncology, Inc. (CGON)

Reporting relationship: Director
Issuer ticker: CGON
Reported as of: 05 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Jun 2025, 17:00:40 UTC
Prior SEC filing: 22 May 2025
Next SEC filing: 13 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Joshua F. Patterson, Attorney-in-Fact for Leonard Post

Key filing fact

Leonard E. Post filed Form 4 for CG Oncology, Inc. (CGON) on 06 Jun 2025.

Key facts

This page summarizes Leonard E. Post's Form 4 filing for CG Oncology, Inc. (CGON).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 06 Jun 2025, 17:00.

Change

Previous filing in this sequence was filed on 22 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001235862 Primary reporting owner

POST LEONARD E

Relationship: Director
Address: C/O CG ONCOLOGY, INC., 400 SPECTRUM CENTER DRIVE, SUITE 2040, IRVINE
Signature: /s/ Joshua F. Patterson, Attorney-in-Fact for Leonard Post
Signature date: 05 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CGON transaction Derivative

Director Stock Option (right to buy)

Award

Transaction value: $0
Shares: +24,165
Change %
Price: $0.000000
Shares after: 24,165
Date: 05 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 24,165
Exercise price: $26.63
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 1 footnote

Footnote F1

1/12th of the total number of shares of common stock subject to the option vest monthly following June 5, 2025, the date of grant (or, in the event the next annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of this stock option will vest on the date of such annual meeting of the Issuer's stockholders), subject to the Reporting Person's continuous service to the Issuer through each vesting date.